𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I studies of porfiromycin (NSC—56410) in solid tumors

✍ Scribed by Dr. Theodor B. Grage; Arthur J. Weiss; William Wilson; Vernon Reynolds


Publisher
John Wiley and Sons
Year
1975
Tongue
English
Weight
354 KB
Volume
7
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


A phase I study of gemcitabine and docet
✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

Phase I study of CI-958 in children and
✍ Carola A. S. Arndt; Mark D. Krailo; Wen Liu-Mares; Peter M. Anderson; Gregory H. 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB 👁 2 views

BACKGROUND. CI-958 is a synthetic intercalating agent of a new chemical class, the benzopyranoindazoles, with promising preclinical activity. Its mechanism of action is thought to be stabilization of the cleavable complex of DNA with topoisomerase II, as well as DNA helicase blockade. It is thought

Phase I trial of trimetrexate in pediatr
✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma